MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025

MAIA Biotechnology, Inc.

Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.
Trial evaluates THIO sequenced with CPI cemiplimab in advanced NSCLC patients after 2+ prior therapies.
Corporate presentation posted to MAIA website on June 2, 2025, filed as Exhibit 99.2.
Poster available on MAIA's website from June 2, 2025 onward.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.